Salute e Benessere

Endo Launches Bivalirudin Injection in Ready-to-Use Vials

In May 2023, Endo executed agreements with MAIA Pharmaceuticals, Inc. and Gland Pharma Limited, India to commercialize ready-to-use bivalirudin in the U.S. The product, manufactured by Gland Pharma Limited, is an anticoagulant (thrombin inhibitor) that helps prevent the formation of blood clots. It is used to prevent blood clots in people with severe chest pain or other conditions who are undergoing an angioplasty procedure. InMay 2023, Endo executed agreements with MAIA Pharmaceuticals, Inc...
PR Newswire
18/07/2023

Amarin Appoints Patrick Holt as President and Chief Executive Officer

Mr. Holt brings more than 25 years of leadership in the life sciences industry and significant international operating experience. He most recently served as president of Cordis, Cardinal Health's global interventional cardiovascular business where he led a turnaround of the business, followed by a transaction process which led to its successful sale. Mr. Holt previously held a variety of senior executive positions across biopharmaceuticals and vaccines at Allergan and Merck.“We are...
Nasdaq GlobeNewswire
18/07/2023

Amarin Implements Organizational Restructuring to Strengthen the Company While…

-- Focus on Gaining Access for European Patients in Remaining Geographies and Strategic Use of Commercial Resources -- -- Maximizes Cash Flow Opportunity Through Streamlined Model in U.S. ---- Company Expects Restructuring to Drive Annual Cost Savings of Approximately $40 Million ---- Announces Preliminary Earnings Results for Second Quarter 2023 ---- Company to Host Conference Call Today at 5:00 p.m. EDT -- DUBLIN, Ireland and BRIDGEWATER, N.J., July18, 2023(GLOBE...
Nasdaq GlobeNewswire
18/07/2023

Vital Signs Monitoring Market to Witness Rebound Sales in the Upcoming Years…

To Know More, Download the Free Sample Report: https://www.arizton.com/request-sample/3856 To Know More, Download the Free Sample Report:https://www.arizton.com/request-sample/3856 Browse In-Depth TOC on Vital Signs Monitoring Devices Market 159 – Tables 158 – Charts 370 – Pages The vital sign monitoring devices landscape has become more complex and competitive after the COVID-19 outbreak. Although the demand for vital monitors during the pre-pandemic phase was...
PR Newswire
18/07/2023

C-Path Integrates European Offices to Optimize Global Operations and…

Shortly after it was founded in 2005, C-Path began forging relationships with European entities. In 2007, C-Path's Predictive Safety Testing Consortium was the first collaboration to submit through the pilot qualification procedures an evidence package for seven kidney safety biomarkers to the U.S. Food and Drug Administration, the European Medicines Agency (EMA) and the Pharmaceuticals and Medical Devices Agency in Japan. In May 2008, EMA issued a final conclusions statement for these…
PR Newswire
18/07/2023

Sanofi: Information concerning the total number of voting rights and shares –…

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of theCode de commerce(the French Commercial Code) and article 223-16 of theRèglementgénéral de l'Autorité des Marchés Financiers(Regulation of the French stock market authority) Sanofi a Frenchsociété anonymewith a registered share capital of 2,521,494,572 € Registered office : 46, avenue de la Grande Armée - 75017 Paris - France...
Nasdaq GlobeNewswire
18/07/2023

IPSEN - Buy-back programme - Art 5 of MAR - Week 28 - 2023

Aggregatedpresentationbydayandbymarket NameofissuerIdentificationcodeof issuer(Legal Entity Identifier)Day of transactionIdentificationcodeof financialinstrumentAggregated daily volume(innumber of shares)Dailyweightedaveragepriceof the purchased shares *Market(MICCode)IPSEN549300M6SGDPB4Z94P1110/07/2023FR0010259150511108.65AQEUIPSEN549300M6SGDPB4Z94P11...
Nasdaq GlobeNewswire
18/07/2023

Virbac : Revenue up about 2% during the second quarter and stable at the end of…

KEY FIGURES Revenue in first half of 2023 - Provisional1 €609 .9MGrowth at constant exchange ratesand scope 2 +0 .2%includingcompanion animals ~-1.0%farm animals ~+0.0%Growth at constantexchange rates+0 .2%Overallchange-1.0% 1 provisional unaudited revenue that may be adjusted due to the temporary downtime of some of our information systems...
Nasdaq GlobeNewswire
18/07/2023

Invitation to Idorsia's HY 2023 Financial Results webcast and conference call

Idorsia will publish its half year financial results 2023 on Tuesday July 25, 2023, at 07:00 CEST. An investor conference call and webcast will be held to discuss the results on the same day.Date: Tuesday , July 25 , 2023 Time: 15:00 CEST / 14:00 BST / 09:00 EDT The call will start with presentations by senior management, followed by a Q&A session.To support your preparations, the consensus estimates can be found under:www...
Nasdaq GlobeNewswire
18/07/2023

Transactions in connection with and conclusion of share buy-back program

Company announcement no. 35 - 2318 July 2023 Transactions in connection with and conclusion of share buy-back program On 8 May 2023 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company announcement no. 17 - 23. The program will be executed in accordance with the principles of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe...
Nasdaq GlobeNewswire
18/07/2023

Adhesion Barrier Market worth $0.9 billion | MarketsandMarkets

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=208132543 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=208132543 Browse in-depth TOC on "Adhesion Barrier Market"180 - Tables 45 - Figures 210 - Pages Adhesion Barrier Market Scope: By product, the synthetic adhesion barriers accounted for the largest share of the adhesion barrier market, in 2022. Based on products, the adhesion...
PR Newswire
18/07/2023

Neurolief Announces Positive Results from the MOOD Trial Interim Analysis: Brain…

At a meeting of the study's independent Data Monitoring Committee (DMC), statistical results from a pre-planned efficacy and safety interim analysis were reviewed. Based on data from 80% of the originally planned study sample size, the DMC issued a recommendation to continue patient enrollment up to the final planned sample size, as the interim results are "positively favorable". Full study results will be announced and submitted to the FDA and CE after the last patient completes the…
PR Newswire
18/07/2023

ALZpath Announces New Funding from the Alzheimer's Drug Discovery Foundation…

The investment comes at a pivotal time in the advancement of Alzheimer's disease treatments, with Biogen and Eisai's Lecanemab (LEQEMBI®) recently receiving traditional FDA approval, ushering in a new era for the next generation of Alzheimer's treatments. A critical barrier to widespread availability and use of these and other treatments to follow is the difficulty in diagnosing Alzheimer's patients, particularly in the early stages of disease onset, when such treatments may have the most…
PR Newswire
18/07/2023

New research outlines concern over current financial pressures on UK workplace…

A quarter (26%) said that companies trying to save money by cutting staff numbers and bringing in energy cost-cutting measures such as turning lights or heating down (43%), risked compromising safety, particularly in industrial settings. A quarter (26%) said that companies trying to save money by cutting staff numbers and bringing in energy cost-cutting measures such as turning lights or heating down (43%), risked compromising safety, particularly in industrial settings. Other key findings...
PR Newswire
18/07/2023

BVI Expands IOL Capacity with New State of the Art Facility in Belgium

In line with the company's commitment to efficiency, sustainability, and compliance, the new facility was designed to optimize delivery and involved a comprehensive process review aimed at increasing yield and efficiency. BVI also prioritized environmental considerations and implemented various measures to minimize carbon footprint.Affirming BVI's commitment to innovation, the facility further enlarged BVI's integrated IOL research and development (R&D) and manufacturing capabilities...
Nasdaq GlobeNewswire
18/07/2023

JIMMY Introduces H10 Flex, Making Vacuum Cleaning Effortless Like Never Before

To celebrate the launch of H10 Flex, JIMMY is offering a dramatic price reduction of 100 euros (original price: 399.99 euros) starting on July 20th and ending on August 3rd. This special offer is available on platforms including Geekbuying, Geekuying.pl,Geekmaxi, andJimmy.eu. To celebrate the launch of H10 Flex, JIMMY is offering a dramatic price reduction of100 euros(original price:399.99 euros ) starting onJuly 20thand ending onAugust 3rd. This special offer is available on...
PR Newswire
18/07/2023

Sobi publishes Q2 2023 report: Growth and pipeline expansion

Second quarter 2023 Second quarter 2023 Outlook 2023 - updated The outlook includes the newly acquired company CTI and Sobi's right to royalty on net sales of nirsevimab in the US. Investors, analysts and media are invited to participate in a conference call which will include a presentation of the results and a Q&A session at13:00 CEST. The presentation can be followed livehere or afterwards on sobi.com. The slides will be made available on sobi.com prior to the...
PR Newswire
18/07/2023

Irish-US Company Celtic Biotech in French cancer venom trials reports grant…

Dr.Paul Reid, CEO and co-founder at Celtic Biotech said:"We are very pleased to be approved by the EIC for this prestigious European Commission grant award. This is a major validation of our business and product strategy and is in alignment withEurope'sBeating Cancer Plan. Our innovative biologic products will treat cancer patients with advanced disease. Our pre-clinical and clinical investigations to date point to a drug with enormous potential to target aggressive solid...
PR Newswire
18/07/2023

Leucid Bio Appoints Filippo Petti as Chief Executive Officer

Prior to Celyad Oncology SA, Mr. Petti spent several years as a healthcare investment banker at Wells Fargo Securities and William Blair & Company, where he specialised in working with cell and gene therapy companies. In addition, Mr. Petti has worked in equity research both at William Blair & Company and Wedbush Securities. He began his career as a research scientist at OSI Pharmaceuticals, Inc. before transitioning to corporate development with the company. Mr. Petti holds a Master of…
PR Newswire
18/07/2023

Synendos Therapeutics AG Co-Founder and SAB Member, Professor Jürg Gertsch…

Synendos was founded to exploit the therapeutic potential of this novel mode of action and is developing SERIs as first-in-class inhibitors that modulate a newly identified drug target in the ECS. By rebalancing and restoring endogenous cannabinoid levels that are dysregulated in certain pathological conditions, this new mode of action has the potential to rebalance brain function in a holistic and pro-homeostatic way to treat neuropsychiatric disorders such as Post-Traumatic Stress Disorder…
PR Newswire
18/07/2023

Enzymatica Interim report Q2/2023: An exciting and important time ahead

"The first half of 2023 showed 58% growth compared to the same period last year. The second quarter is always the weakest of the year for us, as it is the period when the number of colds is the lowest. Still, the second quarter was an intense period. Discussions on launches in some of the world's largest cold markets intensified and our research program continued. In August, we expect the results from two important scientific studies," said Claus Egstrand, CEO of Enzymatica. "The…
PR Newswire
18/07/2023

Notice of Extraordinary General Meeting in Swedish Orphan Biovitrum AB (publ)

Right to participate and registration Right to participate and registration (A) Participation at the meeting venue in person A person who wishes to attend the meeting venue in person or by proxy must If the shareholder is represented by proxy, a written and dated power of attorney signed by the shareholder shall be issued for the proxy. Proxy forms are available at the company's websitewww.sobi.com. If the power of attorney has been issued by a legal entity, a registration...
PR Newswire
18/07/2023

Orexo Q2 2023 Interim Report

Important events after the end of the ­period › ZUBSOLV® reimbursed by Medicaid in Indiana state as of July 1, 2023 Important events after the end of the ­period › ZUBSOLV® reimbursed by Medicaid inIndianastate as ofJuly 1, 2023 Comments by the CEO,Nikolaj Sørensen Good progress towards profitability "During the last three years the uncertainty from the patent litigation against Sun Pharmaceutical to protect the innovation and exclusivity of ZUBSOLV®, has...
PR Newswire
18/07/2023

Sobi intends to carry out a rights issue of approximately SEK 6,000 million and…

On 10 May 2023, Sobi announced that the Company had entered into an agreement, under which Sobi agreed to submit a cash tender offer for all the shares in CTI for a purchase price of approximately USD 1,700 million (corresponding to approximately SEK 18,060 million[2]). The acquisition was completed on 26 June 2023 after successful completion of the tender offer. On10 May 2023, Sobi announced that the Company had entered into an agreement, under which Sobi agreed to submit a cash tender...
PR Newswire
18/07/2023
Altri  Comunicati